TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30860958

Group type: EXPERIMENTAL
Intervention: Life Skills Training
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 150
Study: 26863893

Group type: EXPERIMENTAL
Intervention: Biodentine™
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: ProRoot® White Mineral Trioxide Aggregate (WMTA)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Tempophore™
Number of subjects: 58

Group type: COMPARATOR
Intervention: ProRoot® WMTA
Number of subjects: 58
Study: 25413169

Group type: EXPERIMENTAL
Intervention: Balance training
Number of subjects: 17

Group type: COMPARATOR
Intervention: Seated attention control activity
Number of subjects: 17
Study: 23482914

Group type: EXPERIMENTAL
Intervention: 100 kVp setting and 370 mgI/mL contrast medium
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: 100 kVp setting and 300 mgI/mL contrast medium
Number of subjects: 88

Group type: COMPARATOR
Intervention: 120 kVp setting and 370 mgI/mL contrast medium
Number of subjects: 88

Group type: COMPARATOR
Intervention: 120 kVp setting and 300 mgI/mL contrast medium
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: 100 kVp setting (both 370 mgI/mL and 300 mgI/mL)
Number of subjects: 88
Study: 20553313

Group type: EXPERIMENTAL
Intervention: Endoscopic haemostasis (Group A, n = 37)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Therapeutic barium enema (Group B, n = 11)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Endoscopic haemostasis and therapeutic barium enema (Group C, n = 9)
Number of subjects: 57
Study: 19153029

Group type: EXPERIMENTAL
Intervention: Yunnan Baiyao capsules
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 87
Study: 17302691

Group type: EXPERIMENTAL
Intervention: Tuned waveform
Number of subjects: 34

Group type: COMPARATOR
Intervention: 50/50% tilt waveform
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Tuned waveform (in patients with DFT >= 15 J)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 34
Study: 15049437

Group type: EXPERIMENTAL
Intervention: Solutab tablet (875/125) taken intact or after prior dispersal
Number of subjects: 48

Group type: COMPARATOR
Intervention: Augmentan film-coated tablet (875/125)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both formulations (Solutab and Augmentan)
Number of subjects: 48
Study: 11426528

Group type: EXPERIMENTAL
Intervention: Cladribine (2‐CdA)
Number of subjects: 0
Study: 9684058

Group type: EXPERIMENTAL
Intervention: rt-PA treatment
Number of subjects: 87

Group type: COMPARATOR
Intervention: NINDS trial endpoint
Number of subjects: 87
Study: 8006280

Group type: EXPERIMENTAL
Intervention: 50 mg/day of aspirin for 8 days
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (not treated with aspirin)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Very low dose aspirin therapy during pacing
Number of subjects: 42
Study: 2552802

Group type: EXPERIMENTAL
Intervention: Urinastatin (supplemental)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (cisplatin without urinastatin)
Number of subjects: 0
Study: 1107362

Group type: EXPERIMENTAL
Intervention: Pirprofen
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31397931

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mycophenolate (MPA)
Number of subjects: 0
Study: 29058175

Group type: EXPERIMENTAL
Intervention: Ribociclib plus letrozole
Number of subjects: 668

Group type: COMPARATOR
Intervention: Placebo plus letrozole
Number of subjects: 668
Study: 25557878

Group type: EXPERIMENTAL
Intervention: Immediately loaded implants (test group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed loaded implants (control group)
Number of subjects: 0
Study: 24435025

Group type: EXPERIMENTAL
Intervention: Personal health record
Number of subjects: 170

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 170
Study: 21862415

Group type: EXPERIMENTAL
Intervention: Eribulin mesylate (1.4 mg/m²) administered as a 2- to 5-minute intravenous infusion on days 1, 8, and 15 of a 28-day cycle.
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Eribulin mesylate (1.4 mg/m²) administered on days 1 and 8 of a 21-day cycle.
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Eribulin mesylate (1.4 mg/m²) administered on days 1, 8, and 15 of a 28-day cycle.
Number of subjects: 103
Study: 19860600

Group type: EXPERIMENTAL
Intervention: Dutch Geriatric Intervention Programme (DGIP)
Number of subjects: 0
Study: 18046087

Group type: EXPERIMENTAL
Intervention: Fish oil (10 mL/d) in group I
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (no fish oil) in group II
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (healthy children) in group III
Number of subjects: 41
Study: 15615766

Group type: EXPERIMENTAL
Intervention: Active conservative treatment (pelvic floor muscle training and bladder training)
Number of subjects: 747

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 747
Study: 14646651

Group type: EXPERIMENTAL
Intervention: Single dose of 8 mg IV dexamethasone 1 hour before the operation
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Single dose of 8 mg IV dexamethasone at the beginning of the operation
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 3 doses of 8 mg IV dexamethasone 1 hour before the operation, and 24 and 48 hours after the operation
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 3 doses of 8 mg IV dexamethasone at the beginning of the operation, and 24 and 48 hours after the operation
Number of subjects: 60

Group type: COMPARATOR
Intervention: 3 doses of 8 mg IV dexamethasone immediately after the operation, and 24 and 48 hours after the operation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control, no dexamethasone administration before or after the operation
Number of subjects: 60
Study: 10530902

Group type: EXPERIMENTAL
Intervention: Invasion of chorioamniotic plate and amniotic membranes by leukocytes
Number of subjects: 224

Group type: COMPARATOR
Intervention: Normal chorioamniotic plate and amniotic membranes
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Invasion of chorioamniotic tissues by leukocytes
Number of subjects: 224
Study: 7550859

Group type: EXPERIMENTAL
Intervention: Combination therapy with interferon (IFN) and azidothymidine (AZT)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Interferon alone (IFN-alone group)
Number of subjects: 22
Study: 1955549

Group type: EXPERIMENTAL
Intervention: Self migration in sodium hyaluronate (SH)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Centrifugation and swim up (CS)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control (natural intercourse after clomiphene treatment)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: IUI cycles (SH and CS combined)
Number of subjects: 125
Study: 7468702

Group type: EXPERIMENTAL
Intervention: Manual exploration of the uterus
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no manual exploration)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both groups (manual exploration and control)
Number of subjects: 200
Study: 6151847

Group type: EXPERIMENTAL
Intervention: Triazolam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31307883

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine every 4 weeks
Number of subjects: 183

Group type: COMPARATOR
Intervention: Dihydroartemisinin-piperaquine every 12 weeks
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine every 4 weeks after cessation
Number of subjects: 183

Group type: COMPARATOR
Intervention: Dihydroartemisinin-piperaquine every 12 weeks after cessation
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Adverse events in the 4-week group
Number of subjects: 183

Group type: COMPARATOR
Intervention: Adverse events in the 12-week group
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Severe adverse events in the 4-week group
Number of subjects: 183

Group type: COMPARATOR
Intervention: Severe adverse events in the 12-week group
Number of subjects: 183
Study: 29079475

Group type: EXPERIMENTAL
Intervention: HD‐tPNS (1 mA)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 16
Study: 27418817

Group type: EXPERIMENTAL
Intervention: Home-based multicomponent COPD self-management program
Number of subjects: 345

Group type: COMPARATOR
Intervention: Usual management as per the center's routine practice
Number of subjects: 345
Study: 24401721

Group type: EXPERIMENTAL
Intervention: Coupled plasma filtration adsorption (CPFA)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Coupled plasma filtration adsorption (CPFA) with dose >0.18 L/kg/day
Number of subjects: 192
Study: 22246943

Group type: EXPERIMENTAL
Intervention: Brimonidine/timolol
Number of subjects: 15

Group type: COMPARATOR
Intervention: Dorzolamide/timolol
Number of subjects: 15
Study: 20465146

Group type: EXPERIMENTAL
Intervention: Stages of change in fruit/vegetable consumption
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Self-efficacy
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Decisional balance
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Processes related to fruit/vegetable consumption
Number of subjects: 700
Study: 17350481

Group type: EXPERIMENTAL
Intervention: Allopurinol (300 mg/day, titrated to 100 mg TDS)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 38
Study: 15732035

Group type: EXPERIMENTAL
Intervention: Combination mycophenolate mofetil and prednisone (MMF-P)
Number of subjects: 17
Study: 12783343

Group type: EXPERIMENTAL
Intervention: Microtransducer manometry
Number of subjects: 215

Group type: COMPARATOR
Intervention: Perfusion manometry
Number of subjects: 215
Study: 10561297

Group type: EXPERIMENTAL
Intervention: Paclitaxel 200 mg/m² IV over 3 hours for eight cycles (24 weeks)
Number of subjects: 209

Group type: COMPARATOR
Intervention: CMFP combination chemotherapy (cyclophosphamide 100 mg/m²/d orally on days 1 to 14, methotrexate 40 mg/m² IV on days 1 and 8, fluorouracil 600 mg/m² IV on days 1 and 8, and prednisone 40 mg/m²/d orally on days 1 to 14) for six cycles (24 weeks)
Number of subjects: 209
Study: 8702043

Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ) antimalarial treatment and chemoprophylaxis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mefloquine (MQ) antimalarial treatment and chemoprophylaxis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ) and Mefloquine (MQ) antimalarial treatment and chemoprophylaxis
Number of subjects: 0
Study: 1748064

Group type: EXPERIMENTAL
Intervention: 600 mg ponalrestat once daily for 12 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 7077553

Group type: EXPERIMENTAL
Intervention: Lamaze classes (n = 22)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Red Cross parenting classes (n = 7)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Brief Lamaze training (n = 10)
Number of subjects: 49

Group type: COMPARATOR
Intervention: No training (n = 10)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Red Cross classes (n = 7)
Number of subjects: 49
Study: 31399071

Group type: EXPERIMENTAL
Intervention: ESTEEM intervention (10-session skills-building intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ESTEEM intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Community mental health treatment and HIV counseling and testing
Number of subjects: 0
Study: 28114648

Group type: EXPERIMENTAL
Intervention: Patient intervention (telephone-based focusing on weight management, physical activity, and cognitive behavioral pain management)
Number of subjects: 537

Group type: EXPERIMENTAL
Intervention: Provider intervention (electronic delivery of patient-specific osteoarthritis treatment recommendations)
Number of subjects: 537

Group type: EXPERIMENTAL
Intervention: Patient-provider intervention
Number of subjects: 537

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 537
Study: 26478683

Group type: EXPERIMENTAL
Intervention: Transvaginal hybrid-NOTES cholecystectomy (TVC)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Needlescopic/3-trocar cholecystectomies (NC)
Number of subjects: 100
Study: 23340519

Group type: EXPERIMENTAL
Intervention: 10 mg dose of methylphenidate hydrochloride (MPH)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 8-week MPH treatment (follow-up for 7 patients)
Number of subjects: 23
Study: 20002693

Group type: EXPERIMENTAL
Intervention: Restorative proctocolectomy with ileo-anal anastomosis (IPAA)
Number of subjects: 156
Study: 19389209

Group type: EXPERIMENTAL
Intervention: Liberal transfusion (hemoglobin threshold of 10.0 g per dL)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Restrictive transfusion (hemoglobin threshold of 8.0 g per dL)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Liberal transfusion
Number of subjects: 120

Group type: COMPARATOR
Intervention: Restrictive transfusion
Number of subjects: 120
Study: 17535278

Group type: EXPERIMENTAL
Intervention: 0.2% GTN ointment
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study: 14741043

Group type: EXPERIMENTAL
Intervention: LPS (20 units/kg of body mass)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 11339416

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg b.i.d., clarithromycin 250 mg b.i.d., bismuth subcitrate 240 mg b.i.d. and tetracycline 500 mg b.i.d. (OCBT) for 2 weeks
Number of subjects: 221

Group type: COMPARATOR
Intervention: Ranitidine 300 mg b.i.d., metronidazole 500 mg b.i.d, bismuth subcitrate 240 mg b.i.d. and tetracycline 500 mg b.i.d. (RMBT2) for 2 weeks
Number of subjects: 221

Group type: COMPARATOR
Intervention: Ranitidine 300 mg b.i.d., metronidazole 500 mg b.i.d, bismuth subcitrate 240 mg b.i.d. and tetracycline 500 mg b.i.d. (RMBT3) for 3 weeks
Number of subjects: 221
Study: 11072531

Group type: EXPERIMENTAL
Intervention: ISDN-SR 120 mg
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: ISDN-SR 120 mg once-daily
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: ISDN-SR 480 mg a day (4-times-daily)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 38
Study: 7659429

Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCA)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Epidural opioid analgesia (EOA) with boluses of preservative-free morphine or bupivacaine (1:16% + 2 micrograms/ml fentanyl)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Various treatments (including anxiolytics)
Number of subjects: 202
Study: 1657528

Group type: EXPERIMENTAL
Intervention: Lidoflazine (calcium entry blocker) administered intravenously after restoration of spontaneous circulation
Number of subjects: 520

Group type: COMPARATOR
Intervention: Placebo administered intravenously after restoration of spontaneous circulation
Number of subjects: 520
Study: 6755999

Group type: EXPERIMENTAL
Intervention: Loperamide
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Diphenoxylate
Number of subjects: 27

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Comparison between Loperamide and Diphenoxylate
Number of subjects: 27
Study: 30365356

Group type: EXPERIMENTAL
Intervention: High-dose iron sucrose (400 mg monthly)
Number of subjects: 2141

Group type: COMPARATOR
Intervention: Low-dose iron sucrose (0 to 400 mg monthly)
Number of subjects: 2141
Study: 29991700

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with autologous stem cell transplantation (ASCT)
Number of subjects: 295

Group type: COMPARATOR
Intervention: Maintenance chemotherapy (MT)
Number of subjects: 295
Study: 27483130

Group type: EXPERIMENTAL
Intervention: Guanfacine immediate-release (GUAN-IR) 1-3 mg/day
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Dexmethylphenidate extended-release (DMPH) 5-20 mg/day
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Combination therapy (COMB)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 207
Study: 23995585

Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted tipranavir
Number of subjects: 115
Study: 23180066

Group type: EXPERIMENTAL
Intervention: Granisetron
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 19879013

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with cisplatin and gemcitabine (arm A)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Induction chemoradiotherapy with cisplatin and vinorelbine (arm B)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Induction chemoradiotherapy with carboplatin and paclitaxel (arm C)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Arm A
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Arm B
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Arm C
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 46
Study: 19189526

Group type: EXPERIMENTAL
Intervention: Smoking pregnant women
Number of subjects: 50

Group type: COMPARATOR
Intervention: Nonsmoking pregnant women
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Smoking mothers
Number of subjects: 50

Group type: COMPARATOR
Intervention: Nonsmoking mothers
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Umbilical cord blood of infants born to smoking women
Number of subjects: 50

Group type: COMPARATOR
Intervention: Umbilical cord blood of infants born to nonsmoking women
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cord blood of smoking mothers
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cord blood of nonsmoking mothers
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Correlation in nonsmoking group
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Correlation in smoking group
Number of subjects: 50
Study: 15848906

Group type: EXPERIMENTAL
Intervention: Reduced overall treatment time (OTT) of radiotherapy (9.5, 6.5, and 5.5 weeks)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: High EGFr and low E-cadherin expression
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: High EGFr or low E-cadherin
Number of subjects: 209
Study: 12612272

Group type: EXPERIMENTAL
Intervention: Brief sleep intervention
Number of subjects: 156
Study: 10596772

Group type: EXPERIMENTAL
Intervention: Slow Deep Breathing (n = 18)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Counting Breaths (n = 16)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control (n = 12)
Number of subjects: 46
Study: 8982752

Group type: EXPERIMENTAL
Intervention: 50 micrograms ethinyl oestradiol (EE)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Combined pill containing 30 micrograms EE and 150 micrograms levonorgestrel (LNG)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 1290178

Group type: EXPERIMENTAL
Intervention: A/S 1 x 3 g (single shot)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: A/S 3 x 3 g
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: A/S 3 x 3 g for 3 days (Part II)
Number of subjects: 85
Study: 6374059

Group type: EXPERIMENTAL
Intervention: Dexamethasone and lorazepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 0
Study: 30836781

Group type: EXPERIMENTAL
Intervention: Mental Contrasting with Implementation Intentions (MCII)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control (solving simple math problems)
Number of subjects: 200
Study: 28038496

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Wait-list (WL)
Number of subjects: 54
Study: 27143742

Group type: EXPERIMENTAL
Intervention: X-Bolt Dynamic Hip Plating System
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sliding hip screw fixation
Number of subjects: 100
Study: 24572187

Group type: EXPERIMENTAL
Intervention: Capitation with pay-for-performance
Number of subjects: 0
Study: 22658587

Group type: EXPERIMENTAL
Intervention: Affect-regulated exercise training (2 supervised sessions and 1 unsupervised session per week for 8 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 20
Study: 20708331

Group type: EXPERIMENTAL
Intervention: Barbed polyglyconate sutures
Number of subjects: 81

Group type: COMPARATOR
Intervention: Polyglactin 910 sutures
Number of subjects: 81
Study: 18400808

Group type: EXPERIMENTAL
Intervention: N(2)O Group
Number of subjects: 394

Group type: COMPARATOR
Intervention: N(2)O-free Group
Number of subjects: 394
Study: 15805331

Group type: EXPERIMENTAL
Intervention: VBUS (Volumetric Bladder Ultrasound)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conventional Catheterization (CC)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: VBUS
Number of subjects: 64

Group type: COMPARATOR
Intervention: CC
Number of subjects: 64
Study: 12405871

Group type: EXPERIMENTAL
Intervention: Contoured foam seat (CFS) used as an insert in a regular highchair
Number of subjects: 4

Group type: COMPARATOR
Intervention: Regular highchair with a thin foam liner
Number of subjects: 4

Group type: COMPARATOR
Intervention: Regular highchair
Number of subjects: 4
Study: 10561719

Group type: COMPARATOR
Intervention: Cultured epithelial allografting using allogeneic cultured cells, grafted on a raw surface after palatoplasty, with a duration of 3 weeks for cell culture and 2-3 weeks for complete healing.
Number of subjects: 9

Group type: COMPARATOR
Intervention: Push-back operation only (control group).
Number of subjects: 9
Study: 8738665

Group type: EXPERIMENTAL
Intervention: Microemulsion cyclosporine
Number of subjects: 302
Study: 8069603

Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI)
Number of subjects: 46

Group type: COMPARATOR
Intervention: No prophylactic cranial irradiation (no PCI)
Number of subjects: 46